NASDAQ:BEAT - BioTelemetry Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$66.33 -2.02 (-2.96 %)
(As of 01/22/2019 10:36 AM ET)
Previous Close$68.35
Today's Range$66.07 - $67.86
52-Week Range$29.85 - $74.73
Volume2,183 shs
Average Volume445,119 shs
Market Capitalization$2.28 billion
P/E Ratio68.53
Dividend YieldN/A
Beta1.75
BioTelemetry, Inc., a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry service; and event monitoring services to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and pacemaker and international normalized ratio monitoring services to cardiologists and electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, including cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. This segment's centralized services comprise ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices that include event monitors, digital Holter monitors, and mobile cardiac telemetry monitors, as well as a wireless BGM system. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania.

Receive BEAT News and Ratings via Email

Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BEAT
CUSIPN/A
Phone610-729-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$286.78 million
Cash Flow$1.8158 per share
Book Value$7.70 per share

Profitability

Net Income$-15,950,000.00

Miscellaneous

Employees1,600
Market Cap$2.28 billion
OptionableOptionable

BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions

What is BioTelemetry's stock symbol?

BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT."

How were BioTelemetry's earnings last quarter?

BioTelemetry Inc (NASDAQ:BEAT) released its quarterly earnings results on Tuesday, October, 30th. The medical research company reported $0.53 earnings per share for the quarter, beating analysts' consensus estimates of $0.32 by $0.21. The medical research company had revenue of $100 million for the quarter, compared to analysts' expectations of $97.89 million. BioTelemetry had a net margin of 4.34% and a return on equity of 22.56%. The company's revenue was up 23.5% compared to the same quarter last year. During the same period last year, the business earned $0.16 EPS. View BioTelemetry's Earnings History.

When is BioTelemetry's next earnings date?

BioTelemetry is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for BioTelemetry.

What price target have analysts set for BEAT?

5 Wall Street analysts have issued 1-year price objectives for BioTelemetry's stock. Their predictions range from $41.00 to $90.00. On average, they anticipate BioTelemetry's stock price to reach $63.20 in the next twelve months. This suggests that the stock has a possible downside of 4.7%. View Analyst Price Targets for BioTelemetry.

What is the consensus analysts' recommendation for BioTelemetry?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTelemetry.

Has BioTelemetry been receiving favorable news coverage?

Press coverage about BEAT stock has trended very positive on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BioTelemetry earned a news impact score of 3.2 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are some of BioTelemetry's key competitors?

Who are BioTelemetry's key executives?

BioTelemetry's management team includes the folowing people:
  • Mr. Joseph H. Capper, CEO, Pres & Director (Age 55)
  • Ms. Heather C. Getz, Exec. VP & CFO (Age 44)
  • Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Fred Broadway III, Pres of BioTel Heart (Age 49)
  • Mr. Tim Raher, Sr. VP of HR

Who are BioTelemetry's major shareholders?

BioTelemetry's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Summit Creek Advisors LLC (0.60%), Scout Investments Inc. (0.40%), Navellier & Associates Inc (0.10%), Curbstone Financial Management Corp (0.08%), Curbstone Financial Management Corp (0.07%) and Campbell Newman Asset Management Inc. (0.04%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry.

Which institutional investors are selling BioTelemetry stock?

BEAT stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Scout Investments Inc., Louisiana State Employees Retirement System and Curbstone Financial Management Corp. Company insiders that have sold BioTelemetry company stock in the last year include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Insider Buying and Selling for BioTelemetry.

Which institutional investors are buying BioTelemetry stock?

BEAT stock was acquired by a variety of institutional investors in the last quarter, including Navellier & Associates Inc, Meeder Asset Management Inc., Campbell Newman Asset Management Inc., Curbstone Financial Management Corp and State of Alaska Department of Revenue. View Insider Buying and Selling for BioTelemetry.

How do I buy shares of BioTelemetry?

Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTelemetry's stock price today?

One share of BEAT stock can currently be purchased for approximately $66.33.

How big of a company is BioTelemetry?

BioTelemetry has a market capitalization of $2.28 billion and generates $286.78 million in revenue each year. The medical research company earns $-15,950,000.00 in net income (profit) each year or $0.97 on an earnings per share basis. BioTelemetry employs 1,600 workers across the globe.

What is BioTelemetry's official website?

The official website for BioTelemetry is http://www.gobio.com.

How can I contact BioTelemetry?

BioTelemetry's mailing address is 1000 Cedar Hollow Road, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected]


MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  281 (Vote Outperform)
Underperform Votes:  240 (Vote Underperform)
Total Votes:  521
MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel